Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis.

Suppr

超能文献

作者信息

Ismail Azza, Kemp Julie, Sharrack Basil

出版信息

J Neurol. 2009 Oct;256(10):1771-2. doi: 10.1007/s00415-009-5200-9. Epub 2009 Jul 16.

DOI:10.1007/s00415-009-5200-9

PMID:19609591

Abstract

摘要

相似文献

Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis.

J Neurol. 2009 Oct;256(10):1771-2. doi: 10.1007/s00415-009-5200-9. Epub 2009 Jul 16.

Melanoma complicating treatment with natalizumab for multiple sclerosis.

N Engl J Med. 2008 Feb 7;358(6):647-8. doi: 10.1056/NEJMc0706103.

[Treatment of multiple sclerosis with natalizumab (Tysabri) in a setting of melanoma].

Ann Dermatol Venereol. 2008 Oct;135(10):725-6. doi: 10.1016/j.annder.2008.07.008. Epub 2008 Sep 16.

How Tysabri survived.

Nat Biotechnol. 2009 Nov;27(11):986. doi: 10.1038/nbt1109-986.

Melanoma, eruptive naevi and natalizumab: Causal relation or coincidence?

Australas J Dermatol. 2017 Nov;58(4):330-331. doi: 10.1111/ajd.12724. Epub 2017 Sep 19.

More on melanoma with transdifferentiation.

N Engl J Med. 2008 Jul 3;359(1):99; author reply 99-100. doi: 10.1056/NEJMc086089.

[Natalizumab in multiple sclerosis: the second treatment revolution].

Presse Med. 2008 Jan;37(1 Pt 2):81-4. doi: 10.1016/j.lpm.2007.10.004. Epub 2007 Nov 26.

[Immunosuppression with monoclonal antibodies in multiple sclerosis].

Rev Neurol (Paris). 2007 Jun;163(6-7):682-7. doi: 10.1016/s0035-3787(07)90480-4.

Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?

Mult Scler. 2009 Dec;15(12):1532-3. doi: 10.1177/1352458509347154.

[Natalizumab (Tysabri)].

Ugeskr Laeger. 2007 Sep 17;169(38):3184-7.

引用本文的文献

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Vaccines (Basel). 2020 Dec 26;9(1):12. doi: 10.3390/vaccines9010012.

Multiple Sclerosis Treatment and Melanoma Development.

Int J Mol Sci. 2020 Apr 22;21(8):2950. doi: 10.3390/ijms21082950.

Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).

Cancer Med. 2017 Jul;6(7):1541-1551. doi: 10.1002/cam4.1098. Epub 2017 Jun 20.

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Mult Scler Int. 2015;2015:809252. doi: 10.1155/2015/809252. Epub 2015 Sep 21.

Immunogenicity and other problems associated with the use of biopharmaceuticals.

Ther Adv Drug Saf. 2011 Jun;2(3):113-28. doi: 10.1177/2042098611406318.

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.

Patient Relat Outcome Meas. 2014 Apr 4;5:25-33. doi: 10.2147/PROM.S41768. eCollection 2014.

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

Clin Exp Immunol. 2014 Mar;175(3):397-407. doi: 10.1111/cei.12206.

Association of melanoma and natalizumab therapy in the Italian MS population: a second case report.

Neurol Sci. 2011 Feb;32(1):181-2. doi: 10.1007/s10072-010-0427-x. Epub 2010 Nov 5.

Natalizumab (Tysabri).

AJNR Am J Neuroradiol. 2010 Oct;31(9):1588-90. doi: 10.3174/ajnr.A2226. Epub 2010 Aug 5.

[Therapeutic monoclonal antibodies in clinical neurology].

Nervenarzt. 2010 Jun;81(6):753-64; quiz 765-6. doi: 10.1007/s00115-010-2947-2.

本文引用的文献

More on melanoma with transdifferentiation.

N Engl J Med. 2008 Jul 3;359(1):99; author reply 99-100. doi: 10.1056/NEJMc086089.

Melanoma complicating treatment with natalizumab for multiple sclerosis.

N Engl J Med. 2008 Feb 7;358(6):647-8. doi: 10.1056/NEJMc0706103.

Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?

Drug Discov Today. 2007 Jul;12(13-14):569-76. doi: 10.1016/j.drudis.2007.05.001. Epub 2007 Jun 26.

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.

Arch Neurol. 2006 Oct;63(10):1383-7. doi: 10.1001/archneur.63.10.1383.

Regulation of integrin activity by MIA.

J Biol Chem. 2006 Apr 28;281(17):11669-77. doi: 10.1074/jbc.M511367200. Epub 2006 Mar 3.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

N Engl J Med. 2006 Mar 2;354(9):911-23. doi: 10.1056/NEJMoa044396.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397.

Natalizumab and progressive multifocal leukoencephalopathy.

N Engl J Med. 2005 Jul 28;353(4):432-3. doi: 10.1056/NEJMc055235. Epub 2005 Jun 9.

Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients.

Dermatol Surg. 2004 Apr;30(4 Pt 2):622-7. doi: 10.1111/j.1524-4725.2004.30147.x.

Transcriptional regulation of the alpha 4 integrin subunit gene in the metastatic spread of uveal melanoma.

Anticancer Res. 1998 Sep-Oct;18(5A):3539-47.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis.

J Neurol. 2009 Oct;256(10):1771-2. doi: 10.1007/s00415-009-5200-9. Epub 2009 Jul 16.

Melanoma complicating treatment with natalizumab for multiple sclerosis.

N Engl J Med. 2008 Feb 7;358(6):647-8. doi: 10.1056/NEJMc0706103.

[Treatment of multiple sclerosis with natalizumab (Tysabri) in a setting of melanoma].

Ann Dermatol Venereol. 2008 Oct;135(10):725-6. doi: 10.1016/j.annder.2008.07.008. Epub 2008 Sep 16.

How Tysabri survived.

Nat Biotechnol. 2009 Nov;27(11):986. doi: 10.1038/nbt1109-986.

Melanoma, eruptive naevi and natalizumab: Causal relation or coincidence?

Australas J Dermatol. 2017 Nov;58(4):330-331. doi: 10.1111/ajd.12724. Epub 2017 Sep 19.

More on melanoma with transdifferentiation.

N Engl J Med. 2008 Jul 3;359(1):99; author reply 99-100. doi: 10.1056/NEJMc086089.

[Natalizumab in multiple sclerosis: the second treatment revolution].

Presse Med. 2008 Jan;37(1 Pt 2):81-4. doi: 10.1016/j.lpm.2007.10.004. Epub 2007 Nov 26.

[Immunosuppression with monoclonal antibodies in multiple sclerosis].

Rev Neurol (Paris). 2007 Jun;163(6-7):682-7. doi: 10.1016/s0035-3787(07)90480-4.

Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?

Mult Scler. 2009 Dec;15(12):1532-3. doi: 10.1177/1352458509347154.

[Natalizumab (Tysabri)].

Ugeskr Laeger. 2007 Sep 17;169(38):3184-7.

引用本文的文献

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Vaccines (Basel). 2020 Dec 26;9(1):12. doi: 10.3390/vaccines9010012.

Multiple Sclerosis Treatment and Melanoma Development.

Int J Mol Sci. 2020 Apr 22;21(8):2950. doi: 10.3390/ijms21082950.

Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).

Cancer Med. 2017 Jul;6(7):1541-1551. doi: 10.1002/cam4.1098. Epub 2017 Jun 20.

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Mult Scler Int. 2015;2015:809252. doi: 10.1155/2015/809252. Epub 2015 Sep 21.

Immunogenicity and other problems associated with the use of biopharmaceuticals.

Ther Adv Drug Saf. 2011 Jun;2(3):113-28. doi: 10.1177/2042098611406318.

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.

Patient Relat Outcome Meas. 2014 Apr 4;5:25-33. doi: 10.2147/PROM.S41768. eCollection 2014.

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

Clin Exp Immunol. 2014 Mar;175(3):397-407. doi: 10.1111/cei.12206.

Association of melanoma and natalizumab therapy in the Italian MS population: a second case report.

Neurol Sci. 2011 Feb;32(1):181-2. doi: 10.1007/s10072-010-0427-x. Epub 2010 Nov 5.

Natalizumab (Tysabri).

AJNR Am J Neuroradiol. 2010 Oct;31(9):1588-90. doi: 10.3174/ajnr.A2226. Epub 2010 Aug 5.

[Therapeutic monoclonal antibodies in clinical neurology].

Nervenarzt. 2010 Jun;81(6):753-64; quiz 765-6. doi: 10.1007/s00115-010-2947-2.

本文引用的文献

More on melanoma with transdifferentiation.

N Engl J Med. 2008 Jul 3;359(1):99; author reply 99-100. doi: 10.1056/NEJMc086089.

Melanoma complicating treatment with natalizumab for multiple sclerosis.

N Engl J Med. 2008 Feb 7;358(6):647-8. doi: 10.1056/NEJMc0706103.

Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?

Drug Discov Today. 2007 Jul;12(13-14):569-76. doi: 10.1016/j.drudis.2007.05.001. Epub 2007 Jun 26.

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.

Arch Neurol. 2006 Oct;63(10):1383-7. doi: 10.1001/archneur.63.10.1383.

Regulation of integrin activity by MIA.

J Biol Chem. 2006 Apr 28;281(17):11669-77. doi: 10.1074/jbc.M511367200. Epub 2006 Mar 3.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

N Engl J Med. 2006 Mar 2;354(9):911-23. doi: 10.1056/NEJMoa044396.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397.

Natalizumab and progressive multifocal leukoencephalopathy.

N Engl J Med. 2005 Jul 28;353(4):432-3. doi: 10.1056/NEJMc055235. Epub 2005 Jun 9.

Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients.

Dermatol Surg. 2004 Apr;30(4 Pt 2):622-7. doi: 10.1111/j.1524-4725.2004.30147.x.

Transcriptional regulation of the alpha 4 integrin subunit gene in the metastatic spread of uveal melanoma.

Anticancer Res. 1998 Sep-Oct;18(5A):3539-47.